Previous 10 | Next 10 |
BioDelivery Sciences International (NASDAQ:BDSI) has entered into an agreement with Dr. Reddy’s Laboratories to acquire the U.S. and Canadian rights to ELYXYB (celecoxib oral solution). ELYXYB is the only FDA-approved ready-to-use oral solution for the acute treatment of...
The only FDA-approved, ready-to-use oral solution for the acute treatment of migraine with or without aura in adults First step to building a growth platform in Neurology Patent protection until 2036 RALEIGH, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- BioDelivery Scie...
RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its second quarter 2021 ...
Penny stocks have a poor reputation, but the chance of finding a diamond in the rough keeps some traders coming back to them again and again. Thankfully, with a bit of critical-minded sifting through the endless dunes of forgettable small-cap stocks, investors can find a few worth consideri...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
BDSI has been doing very well with product sales. However, it has never seen the peak it saw during approvals of lead drugs. Emerging biopharma companies often do not transition to commercial-stage companies too well. For further details see: BioDelivery Sciences: Clinic...
The biotech industry saw solid growth last year driven by the demand for therapies to combat COVID-19. But advances in technology helped biotech companies deliver impressive drug candidates for treating other serious ailments too. Consequently, Wall Street analysts expect the biotech industry...
This Biodelivery Sciences (NASDAQ: BDSI) report helps #investors and #traders identify both opportunity, and potential #redflags by using the price action of the stock. The trading plans for BDSI have risk controls, and that make these observations both opportunistic a...
The #nextmove in a #stockprice is often identifiable in advance. This Biodelivery Sciences (NASDAQ: BDSI) report attempts to do that, and in the process help investors learn how price acton can be revealing. Trading plans for BDSI make these observations acti...
News, Short Squeeze, Breakout and More Instantly...
BioDelivery Sciences International Inc. Company Name:
BDSI Stock Symbol:
NASDAQ Market:
BioDelivery Sciences International Inc. Website:
35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the developm...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...